Alexander M Menzies

Alexander M Menzies

UNVERIFIED PROFILE

Are you Alexander M Menzies?   Register this Author

Register author
Alexander M Menzies

Alexander M Menzies

Publications by authors named "Alexander M Menzies"

Are you Alexander M Menzies?   Register this Author

98Publications

3069Reads

28Profile Views

Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes.

J Clin Endocrinol Metab 2019 Nov;104(11):5499-5506

Melanoma Institute Australia and the University of Sydney, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2019-00423DOI Listing
November 2019

Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia.

Cancer Chemother Pharmacol 2019 Apr 19;83(4):693-704. Epub 2019 Jan 19.

Faculty of Medicine and Health, School of Pharmacy, The University of Sydney, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-019-03780-yDOI Listing
April 2019

Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation - Authors' reply.

Lancet Oncol 2018 08;19(8):e367

Disciplines of Medical Oncology, Melanoma Institute Australia, University of Sydney, Sydney, NSW 2065, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30508-4DOI Listing
August 2018

Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy.

Pigment Cell Melanoma Res 2018 07 10;31(4):509-515. Epub 2018 Jan 10.

Department of Medical Oncology, Royal North Shore Hospital, St Leonards, NSW, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/pcmr.12682
Publisher Site
http://dx.doi.org/10.1111/pcmr.12682DOI Listing
July 2018

Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis.

Pituitary 2018 Jun;21(3):274-282

Department of Endocrinology, St Vincent's Hospital, Darlinghurst, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11102-018-0866-6DOI Listing
June 2018

Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma.

Pigment Cell Melanoma Res 2018 05 7;31(3):404-410. Epub 2017 Dec 7.

Melanoma Institute Australia, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12675DOI Listing
May 2018

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.

Lancet Oncol 2018 05 27;19(5):672-681. Epub 2018 Mar 27.

Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia; Medical, Dental and Health Sciences, University of Melbourne, Parkville, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30139-6DOI Listing
May 2018

The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.

Eur J Endocrinol 2018 Feb 29;178(2):173-180. Epub 2017 Nov 29.

Department of Endocrinology, Royal North Shore Hospital, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/EJE-17-0810DOI Listing
February 2018

Leptomeningeal melanoma-A case series in the era of modern systemic therapy.

Pigment Cell Melanoma Res 2018 01 17;31(1):120-124. Epub 2017 Oct 17.

Department of Medical Oncology, Royal North Shore Hospital, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12652DOI Listing
January 2018

Radiological manifestations of immune-related adverse effects observed in patients with melanoma undergoing immunotherapy.

J Med Imaging Radiat Oncol 2017 Dec 11;61(6):759-766. Epub 2017 Oct 11.

Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1754-9485.12653DOI Listing
December 2017

Has the melanoma information tsunami become a maelstrom?

Melanoma Manag 2017 Dec 14;4(4):179-182. Epub 2017 Sep 14.

Melanoma Institute Australia, The University of Sydney, Sydney NSW 20160, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt-2017-0020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094604PMC
December 2017

Immune mediated neuropathy following checkpoint immunotherapy.

J Clin Neurosci 2017 Nov 29;45:14-17. Epub 2017 Jul 29.

Department of Neurology, Royal North Shore Hospital, Sydney, NSW, Australia; The University of Sydney, Sydney, NSW, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jocn.2017.07.014DOI Listing
November 2017

A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy.

Melanoma Res 2017 06;27(3):243-250

aDepartment of Medical Oncology, Royal North Shore Hospital bDepartment of Medical Oncology Melanoma Institute Australia cDepartment of Medical Oncology, The University of Sydney, Sydney, New South Wales, Australia dDepartment of Medical Oncology, Istituto Nazionale Tumori 'Fondazione Pascale', Naples, Campania, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000343DOI Listing
June 2017

Immune checkpoint inhibitors in challenging populations.

Cancer 2017 06 27;123(11):1904-1911. Epub 2017 Feb 27.

Department of Medicine, Melanoma Institute Australia, University of Sydney Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30642DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445005PMC
June 2017

Immune Checkpoint Inhibitors for Brain Metastases.

Curr Oncol Rep 2017 Jun;19(6):38

Royal North Shore Hospital, St Leonards, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-017-0596-3DOI Listing
June 2017

Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.

Cancer 2017 06;123(S11):2118-2129

Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30435DOI Listing
June 2017

Optimum dosing of ipilimumab in melanoma: too little, too late?

Lancet Oncol 2017 05 27;18(5):558-559. Epub 2017 Mar 27.

Melanoma Institute Australia, Royal North Shore and Mater Hospitals, The University of Sydney, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30228-0DOI Listing
May 2017

Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies.

Eur J Cancer 2017 04 23;75:169-178. Epub 2017 Feb 23.

Melanoma Institute Australia, The University of Sydney, NSW, Australia; Genesis Cancer Care, Mater Radiation Oncology, North Sydney, Australia; Mater Hospital, North Sydney NSW, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.01.007DOI Listing
April 2017

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

J Clin Oncol 2017 Mar 30;35(7):709-717. Epub 2016 Sep 30.

Jarushka Naidoo, Kaitlin M. Woo, Tunc Iyriboz, Darragh Halpenny, Jane Cunningham, Jamie E. Chaft, Neil H. Segal, Margaret K. Callahan, Alexander M. Lesokhin, Jonathan Rosenberg, Martin H. Voss, Charles M. Rudin, Hira Rizvi, Xue Hou, Katherine Rodriguez, Melanie Albano, Ruth-Ann Gordon, Charles Leduc, Natasha Rekhtman, Bianca Harris, Jedd D. Wolchok, Michael A. Postow, and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center; Jamie E. Chaft, Neil H. Segal, Margaret K. Callahan, Alexander M. Lesokhin, Jonathan Rosenberg, Martin H. Voss, Charles M. Rudin, Jedd D. Wolchok, Michael A. Postow, and Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Jarushka Naidoo, Sidney Kimmel Cancer Center at Johns Hopkins University, Baltimore, MD; Xuan Wang, Peking University Cancer Hospital and Institute, Beijing; Xue Hou, Sun Yat-sen University Cancer Center, Guangdong Province, People's Republic of China; Xuan Wang, Matteo S. Carlino, Benjamin Y. Kong, and Georgina V. Long, The University of Sydney; Alexander M. Menzies and Alexander D. Guminski, Royal North Shore and Mater Hospital; and Matteo S. Carlino and Benjamin Y. Kong, Westmead and Blacktown Hospitals, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.2005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559901PMC
March 2017

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series.

Br J Cancer 2016 Nov 6;115(11):1280-1284. Epub 2016 Oct 6.

Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione 'G. Pascale', Via Mariano Semmola, 80131 Napoli, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2016.321DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129828PMC
November 2016

Recent Developments in Melanoma Therapy.

JAMA Oncol 2016 Oct;2(10):1259-1260

Melanoma Institute Australia, Sydney, Australia2The University of Sydney, Sydney, Australia3Royal North Shore Hospital, Sydney, Australia4Mater Hospital, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.3418DOI Listing
October 2016

PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma.

Clin Cancer Res 2016 08 9;22(15):3915-23. Epub 2016 Mar 9.

Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia. Sydney Medical School, The University of Sydney, Camperdown, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-1714DOI Listing
August 2016

Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE Study.

Clin Cancer Res 2016 07 4;22(13):3164-71. Epub 2016 Feb 4.

Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, Australia. Sydney Medical School - Westmead, University of Sydney, Sydney, Australia. Faculty of Medicine and Health Sciences, Macquarie University, Sydney Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-1470DOI Listing
July 2016

Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making.

Pathology 2016 Apr 9;48(3):261-6. Epub 2016 Mar 9.

Melanoma Institute Australia, North Sydney, NSW, Australia; Discipline of Pathology, Sydney Medical School, The University of Sydney, NSW, Australia; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pathol.2016.01.001DOI Listing
April 2016

Biology and treatment of BRAF mutant metastatic melanoma.

Melanoma Manag 2016 Mar 12;3(1):33-45. Epub 2016 Feb 12.

Melanoma Institute Australia, North Sydney, NSW 2060, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt.15.38DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097549PMC
March 2016

The molecular profile of metastatic melanoma in Australia.

Pathology 2016 Feb 18;48(2):188-93. Epub 2016 Jan 18.

Melanoma Institute Australia, Sydney, NSW, Australia; The University of Sydney, Sydney, NSW, Australia; Royal North Shore Hospital, Sydney, NSW, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pathol.2015.12.008DOI Listing
February 2016

Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.

JAMA Dermatol 2015 Oct;151(10):1103-9

Department of Dermatology, Westmead Hospital, Sydney, Australia2University of Sydney Medical Faculty, Sydney Medical School, University of Sydney, Sydney, Australia.

View Article

Download full-text PDF

Source
http://archderm.jamanetwork.com/article.aspx?doi=10.1001/jam
Publisher Site
http://dx.doi.org/10.1001/jamadermatol.2015.1745DOI Listing
October 2015

PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.

Clin Cancer Res 2015 Jul 21;21(14):3140-8. Epub 2015 Jan 21.

Melanoma Institute Australia, North Sydney, New South Wales, Australia. Sydney Medical School, the University of Sydney, Sydney, New South Wales, Australia. Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2023DOI Listing
July 2015

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials.

Pigment Cell Melanoma Res 2015 May 22;28(3):245-53. Epub 2014 Dec 22.

Melanoma Institute Australia, Sydney, NSW, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/pcmr.12340
Publisher Site
http://dx.doi.org/10.1111/pcmr.12340DOI Listing
May 2015

Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas.

J Invest Dermatol 2015 Feb 22;135(2):532-541. Epub 2014 Sep 22.

Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, California, USA; Sequencing Center, John Wayne Cancer Institute, Santa Monica, California, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/jid.2014.418DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307785PMC
February 2015

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.

Nat Commun 2014 Dec 2;5:5694. Epub 2014 Dec 2.

1] Precision Cancer Therapy Laboratory, Australian School of Advanced Medicine, Macquarie University, Sydney, New South Wales 2109, Australia [2] Westmead Institute for Cancer Research, The University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms6694DOI Listing
December 2014

The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition.

Cancer 2014 Oct 1;120(20):3142-53. Epub 2014 Jul 1.

Melanoma Institute Australia, Sydney, New South Wales, Australia; Department of Medical Oncology, Crown Princess Mary Cancer Center, Westmead Hospital, Sydney, New South Wales, Australia; University of Sydney, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28851DOI Listing
October 2014

Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma.

Melanoma Res 2014 Oct;24(5):468-74

aWestmead Hospital bWestmead Institute for Cancer Research, Westmead cMelanoma Institute Australia dSydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000110DOI Listing
October 2014

Reply to M. Perier-Muzet et al.

J Clin Oncol 2014 Oct 2;32(28):3203. Epub 2014 Sep 2.

Melanoma Institute Australia; and Sydney Medical School, The University of Sydney, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.56.8477DOI Listing
October 2014

Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors.

Mod Pathol 2014 Sep 17;27(9):1193-202. Epub 2014 Jan 17.

1] Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2013.226DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107197PMC
September 2014

Systemic treatment for BRAF-mutant melanoma: where do we go next?

Lancet Oncol 2014 Aug;15(9):e371-81

Melanoma Institute Australia, Sydney, NSW, Australia; University of Sydney, Sydney, NSW, Australia. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045147007
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(14)70072-5DOI Listing
August 2014

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

Clin Cancer Res 2014 Apr 24;20(7):1965-77. Epub 2014 Jan 24.

Authors' Affiliations: Westmead Institute for Cancer Research, The University of Sydney at Westmead Millennium Institute; Departments of Medical Oncology and Surgical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead; Melanoma Institute Australia; Disciplines of Pathology, Medicine, and Surgery, Sydney Medical School, The University of Sydney, Sydney; Departments of Melanoma and Surgical Oncology and Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-3122DOI Listing
April 2014

Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.

Clin Cancer Res 2014 Apr 28;20(8):2035-43. Epub 2014 Feb 28.

Authors' Affiliation: Melanoma Institute Australia and the University of Sydney, Sydney, Australia.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-13-2054DOI Listing
April 2014

Incidence of new primary melanomas after diagnosis of stage III and IV melanoma.

J Clin Oncol 2014 Mar 2;32(8):816-23. Epub 2013 Dec 2.

Lisa Zimmer and Dirk Schadendorf, University Hospital, University Duisburg-Essen, Essen, Germany; Lauren E. Haydu, Alexander M. Menzies, Richard A. Scolyer, Richard F. Kefford, John F. Thompson, and Georgina V. Long, Melanoma Institute Australia; Alexander M. Menzies, Richard A. Scolyer, Richard F. Kefford, and Georgina V. Long, Sydney Medical School, The University of Sydney; Richard A. Scolyer and John F. Thompson, Royal Prince Alfred Hospital; Lauren E. Haydu and John F. Thompson, The University of Sydney; John F. Thompson, Mater Hospital, Sydney; Richard F. Kefford and Georgina V. Long, Westmead Institute for Cancer Research, Westmead Hospital, Westmead, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.5572DOI Listing
March 2014

Intrapatient homogeneity of BRAFV600E expression in melanoma.

Am J Surg Pathol 2014 Mar;38(3):377-82

*Melanoma Institute Australia Discipline of †Medicine §Pathology #Surgery, The University of Sydney Departments of **Melanoma and Surgical Oncology ‡Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital ∥Department of Medicine, Westmead Hospital ¶Westmead Institute for Cancer Research, Westmead Hospital ††The Kinghorn Cancer Centre, Garvan Institute of Medical Research ‡‡St Vincent's Clinical School, University of New South Wales, Sydney, Australia.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/ajsp/2014/03000/Intrapatient_Ho
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/PAS.0000000000000136DOI Listing
March 2014

Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib.

Cancer 2014 Feb 5;120(4):530-6. Epub 2013 Nov 5.

Westmead Hospital, Westmead, Australia; Melanoma Institute Australia, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28445DOI Listing
February 2014

Molecular biomarkers of prognosis in melanoma: how far are we from the clinic?

Melanoma Res 2013 Dec;23(6):423-5

aThe University of Sydney at Westmead Millennium Institute for Medical Research bMelanoma Institute Australia, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000001DOI Listing
December 2013

Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond.

Eur J Cancer 2013 Oct 16;49(15):3229-41. Epub 2013 Jul 16.

Melanoma Institute Australia, Sydney, Australia; The University of Sydney, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2013.06.027DOI Listing
October 2013

Paradoxical oncogenesis: are all BRAF inhibitors equal?

Pigment Cell Melanoma Res 2013 Sep 19;26(5):611-5. Epub 2013 Jul 19.

Melanoma Institute Australia, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12132DOI Listing
September 2013

New combinations and immunotherapies for melanoma: latest evidence and clinical utility.

Ther Adv Med Oncol 2013 Sep;5(5):278-85

Melanoma Institute Australia, University of Sydney, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834013499637DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3752177PMC
September 2013

Dabrafenib and its potential for the treatment of metastatic melanoma.

Drug Des Devel Ther 2012 11;6:391-405. Epub 2012 Dec 11.

Melanoma Institute Australia, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/DDDT.S38998DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523565PMC
May 2013

BRAF inhibitor activity in V600R metastatic melanoma.

Eur J Cancer 2013 Mar 10;49(5):1073-9. Epub 2012 Dec 10.

Melanoma Institute Australia and Westmead Hospital, University of Sydney, 40 Rocklands Road, North Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2012.11.004DOI Listing
March 2013

Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.

Clin Cancer Res 2012 Jun 24;18(12):3242-9. Epub 2012 Apr 24.

Melanoma Institute Australia, Disciplines of Medicine, Surgery, Pathology, and Westmead Institute for Cancer Research, Westmead Millennium Institute, The University of Sydney, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-12-0052DOI Listing
June 2012

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

J Clin Oncol 2011 Apr 22;29(10):1239-46. Epub 2011 Feb 22.

Melanoma Institute Australia, 40 Rocklands Rd, North Sydney, New South Wales, 2060, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2010.32.4327DOI Listing
April 2011